Vietnam Diabetes Care Drugs And Devices Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Vietnam's diabetes care market covers insulin and GLP-1 agonist therapies, oral antidiabetic drugs, glucometers and test strips, continuous glucose monitoring systems, and related diagnostics. With an estimated 5-6% of the adult population living with diabetes and many more remaining undiagnosed, the country faces a significant and growing disease burden. Domestic spending on diabetes care has been rising steadily as the government expands insurance coverage and patients increasingly seek treatment through both public hospitals and private clinics.

• •Market valued at approximately $0.445 billion in 2025, reflecting a mid-tier share of Southeast Asia's regional diabetes market
• •Growing diabetes prevalence driven by urbanization, sedentary lifestyles, and shifting dietary patterns toward processed foods
• •Expanding public health insurance scheme and private healthcare investment are improving patient access to diagnosis and treatment

Rising per-capita income and greater health awareness are encouraging earlier diagnosis and adherence to long-term treatment regimens. The Vietnamese government's push to universalize health insurance and strengthen primary care networks has reduced out-of-pocket costs and brought more patients into the healthcare system. An aging population and increasing obesity rates are compounding the diabetes epidemic, while foreign direct investment in domestic pharmaceutical manufacturing is improving supply chain reliability.

• •Approximately 1.5-2 million diagnosed diabetics in Vietnam, with an additional estimated 2 million undiagnosed cases representing latent market demand
• •Government health insurance now covers the majority of the population, with reimbursement policies gradually broadening to include newer diabetes medications and devices
• •Foreign and local manufacturers are expanding local production capacity, supported by regulatory incentives and Vietnam's growing role as a regional manufacturing hub

The market splits into drugs (insulin, oral antidiabetics, GLP-1 receptor agonists) and devices (blood glucose meters, test strips, continuous glucose monitors, insulin delivery systems). Urban centers such as Ho Chi Minh City and Hanoi dominate consumption, accounting for a disproportionate share of pharmaceutical and device sales due to higher incomes, greater specialist availability, and better insurance penetration. Secondary cities and emerging industrial zones are growing faster as the middle class expands beyond the two largest metros.

• •Insulin and insulin analogs represent the largest revenue segment, driven by high prevalence of type 2 diabetes requiring progressive therapy escalation
• •Blood glucose monitoring devices, particularly test strips and glucometers, constitute the dominant device category by volume and are widely available in pharmacies nationwide
• •Ho Chi Minh City and Hanoi together account for a majority share of market revenue, with Red River Delta and Southeast regions showing the fastest growth rates

What are the recent trends and outlook?

The market is expected to sustain its 4.69% compound annual growth rate through 2030, supported by continued economic expansion, further insurance penetration, and rising chronic disease management standards. Digital health technologies, including telemedicine platforms and mobile health applications for diabetes self-management, are beginning to influence prescribing patterns and patient engagement. Policy pressures toward mandatory price reductions and increased local manufacturing requirements are shaping supply chains, while the entry of newer drug classes such as GLP-1 receptor agonists is expected to gradually shift the therapeutic mix.

• •Ongoing healthcare infrastructure development and the government's commitment to non-communicable disease programs provide structural support for continued market expansion through 2030
• •Price regulation and mandatory generic substitution policies are expected to compress margins for multinational originator products while expanding overall patient access and volumes
• •Emerging digital therapeutics and telehealth services are likely to complement traditional drug and device sales by improving patient adherence and enabling earlier intervention